Your AI-Trained Oncology Knowledge Connection!
Commentary
Video
Author(s):
Christian Marth, MD, PhD, discusses next steps with pembrolizumab and lenvatinib for use in the advanced or recurrent endometrial cancer treatment paradigm.
Stay up to date on the most recent and practice-changing oncology data
Five Under 5: Top Oncology Videos for the Week of 3/16
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
Emerging ADCs, Biomarker-Driven Treatments, and Diagnostic Advancements Take Center Stage at the SGO Annual Meeting
Naumann Discusses Notable Research Efforts in Endometrial Cancer
Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer
Eribulin and Trabectedin Yield Comparable Real-World OS Outcomes in Advanced Liposarcoma
Physical Functioning Measures May Predict Survival Outcomes, ICANS Risk With CAR T-Cell Therapy in NHL
First-Line Atezolizumab Is Suitable in Platinum-Based Chemotherapy Ineligible mUC
Adjuvant CDK4/6 Inhibitors Lay a Solid Treatment Foundation in HR+, HER2– Breast Cancer